This ELISA kit provides quantitative measurement of interleukin-22 (IL-22) in human samples, supporting research into mucosal immunity, tissue repair, and barrier defense. Because IL-22 is produced by a restricted subset of immune cells — primarily Th22, Th17, and ILC3 populations — and acts on non-hematopoietic epithelial targets, detecting it requires an assay calibrated for the low concentrations typical of both circulation and conditioned media from these relatively rare effector populations.
Detection Range: The 3.9–250 pg/mL range aligns with reported serum IL-22 concentrations in healthy individuals (typically <20 pg/mL) and the elevated levels observed in psoriasis, inflammatory bowel disease, and hepatitis (often 50–200 pg/mL), minimizing the need for sample dilution in most clinical and in vitro contexts.
Sensitivity: At 0.98 pg/mL, the assay detects IL-22 in low-abundance settings such as unstimulated PBMC supernatants or early-phase mucosal inflammation samples where IL-22 induction is just beginning.
Sample Compatibility: Validation across serum, plasma, tissue homogenates, and cell culture supernatants (50–100 µL) enables researchers to correlate circulating IL-22 with local tissue expression and in vitro ILC3 or Th17 polarization outputs within a single experimental framework.
Assay Efficiency: The 1–5 hour protocol and low sample volume accommodate studies using sorted innate lymphoid cells or limited biopsy-derived homogenates where material is scarce.
This kit is particularly suited for studies of psoriasis pathogenesis, IBD mucosal healing mechanisms, and hepatoprotective IL-22 signaling.